Skip to Main Content

Paper Details

Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial.
J Infect Dis
2
2023
ACTIV, COVID-19, coronavirus disease 2019, participants
Author NameAffiliation
Joseph J EronUniversity of North Carolina at Chapel Hill School of Medicine
Eric S DaarLundquist Institute at Harbor-university of california los angeles Medical Center
David A WohlUniversity of North Carolina at Chapel Hill School of Medicine
Judith S CurrierDavid Geffen School of Medicine, University of California los angeles
Judith S CurrierDavid Geffen School of Medicine, University of California los angeles
  • 1 - 5

Datasets

Release 1.2